Factors affecting hospital length of stay following pelvic exenteration surgery

Yükleniyor...
Küçük Resim

Tarih

2018

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

John Wiley and Sons Inc.

Erişim Hakkı

info:eu-repo/semantics/openAccess

Özet

Background and Objectives: Total pelvic exenteration are performed in patients with locally advanced or recurrent pelvic malignances. Many patients have prolong hospital length of stay (LOS), but risk factors are not clearly identified. Methods: From 2002 through 2012, 100 consecutive patients undergoing pelvic exenteration were retrospectively reviewed. A general linear model was used to examine risk factors for prolonged hospital LOS. Results: Among the 100 patients, 51 had gastrointestinal cancer, 14 had genitourinary cancer, 31 had gynecologic cancer, and 4 had sarcoma. Perioperative complications included infection (n = 44), anastomotic leak/fistula (n = 6), wound or flap dehiscence (n = 11), and ileus or bowel obstruction (n = 30). The median (Interquartile range (IQR)) hospital LOS was 15 days (10-21.5 days). On multivariate regression analysis, hospital LOS was significantly prolonged by underweight status, genitourinary cancer or sarcoma diagnosis, ≥2 infections, anastomotic leak/fistula, requiring rehabilitation consult and admission, and ≥2 consultations (P = 0.05). Conclusion: In patients undergoing pelvic exenteration, prolonged hospital LOS is associated with underweight status, genitourinary cancer or sarcoma diagnosis, more than one infection, anastomotic leak/fistula, requiring rehabilitation consult and admission, and more than one consultation. Further study is needed to assess whether minimizing these risk factors can improve hospital LOS in these patients.

Açıklama

Anahtar Kelimeler

Cancer, Hospital length of stay, Pelvic exenteration

Kaynak

Journal of Surgical Oncology

WoS Q Değeri

Q1

Scopus Q Değeri

Q1

Cilt

117

Sayı

3

Künye

Guo, Y., Chang, E., Bozkurt, M., Park, M., Liu, D. ve Fu, J. (2018). Factors affecting hospital length of stay following pelvic exenteration surgery. Journal of Surgical Oncology, 117(3), 529-534.